Category Archives: R&D

Appeal from Asian Civil Society to the DG to discuss the report of United Nations Secretary-General’s High-Level Panel on Access to Medicines (HLP) at the forthcoming EB

Dr. Margaret Chan, Director-General, World Health Organization, Switzerland Dr Poonam Khetrapal Singh, Regional Director of WHO South-East Asia Region, New Delhi Dr. Raymond Busuttil, Chairman of the Executive Board, World Health Organization   18 November 2016 Re: Appeal from Asian Civil Society to … Continue reading

Posted in R&D, Uncategorized, UNHLP report | Leave a comment

The U.S. Is Standing in the Way of Cheaper Drugs for the Poor

By JASON CONE and RAYMOND C. OFFENHEISER, The New York Times|OCT. 27, 2016 Every few months, a drug company gets caught cranking up prices. Most recently, Mylan, the maker of EpiPen, took its turn in the hot seat for raising the … Continue reading

Posted in Innovation, R&D, TPP, Uncategorized, UNHLP report, WHO | Leave a comment

Just the Medicine

How the next president can lower drug prices with the stroke of a pen. By Alicia Mundy, Washington Monthly | Nov/Dec 2016 It’s hard to watch television or read a newspaper these days without seeing stories about outrageous prescription drug … Continue reading

Posted in Bayh Dole Act, Drug prices, Patent, R&D, Uncategorized | Leave a comment

UN High Level Panel report is good prescription for change in access to medicines

Source: PharmaLetter | October 18, 2016 In our weekly expert view piece, Rohit Malpani, director of policy and analysis for Mèdecins Sans Frontiéres Access Campaign, discusses the UN Secretary General’s High-Level Panel report on Access to Medicines and looks at the … Continue reading

Posted in Delinkage, R&D, TPP, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

UN High-Level Panel On Access To Medicines Issues “Landmark” Report

 BY Catherine Saez, Intellectual Property Watch| Sept 14, 2016 The long-awaited report by the United Nations High Level Panel on Access to Medicines was released today, making many recommendations. The panel calls for countries to embrace the policy space available … Continue reading

Posted in R&D, UN General Assembly HLM, Uncategorized | Leave a comment

U.N. panel challenges market-based approach to drug R&D

By Ben Hirschler, Reuters | LONDON The world cannot rely solely on free markets to deliver medicines needed by billions of people in poor countries, so governments should commit to a legally binding convention to coordinate and fund research and … Continue reading

Posted in R&D, Uncategorized | Leave a comment

UN panel probes patents and new drugs

By Marus Low, Business Day Live | August 23, 2016 IT IS often argued that weakening patent monopolies on pharmaceuticals will lead to fewer new medicines being discovered. Whether this is indeed the case, and to what extent, is one … Continue reading

Posted in Drug prices, Patent, R&D, Uncategorized | Leave a comment